Listing of Claims:

This listing of claims will replace all prior versions and listings of claims in the prior application:

1. (currently amended) An isolated, attenuated viral strain of human parainfluenza virus 2**, wherein the viral strain is temperature sensitive and cold adapted**.

2. (currently amended) The isolated, attenuated viral strain of claim 1 which exhibits titers in plaque assays on Vero cells when grown at around 32 °C in a mammalian host cell which are less than about 100 times its titer when grown at around 23 °C in the mammalian host cell, and which ~~is less~~ **are greater** than or equal to about 100 times its titer when grown at around 39 °C in the mammalian host cell.

3. (original) The isolated, attenuated viral strain of claim 1 which exhibits titers in plaque assays on Vero cells when grown at around 39 °C in the mammalian host cell which are less than or equal to about 1.0 pfu/ml.

4. (previously presented) The isolated, attenuated viral strain of claim 1 which is selected from the group of viral strains consisting of those designated C3464, C3490, C3605, and subclones or progeny of any of the aforementioned strains.

5. (canceled)

5 ~~6~~. (original) A vaccine composition comprising the isolated, attenuated viral strain of claim 1 and a pharmaceutically acceptable carrier.

6 ~~7~~. (original) The vaccine composition of claim 5 ~~6~~ further comprising a pharmaceutically acceptable excipient.

7 ~~8~~. (original) The vaccine composition of claim 5 ~~6~~ further comprising a pharmaceutically acceptable adjuvant.

8 ~~9~~. (currently amended) The vaccine composition of claim 5 ~~6~~ wherein the isolated, attenuated viral strain ~~is the strain of claim 2~~ **exhibits titers in plaque assays on Vero cells when grown at around 32°C in a mammalian host cell which are less than about 100 times its titer when grown at around 23°C in the mammalian host cell, and which are greater than or equal to about 100 times its titer when grown at around 39°C in the mammalian host cell**.

9 ~~10~~. (original) The vaccine composition of claim 8 ~~9~~ further comprising a pharmaceutically acceptable excipient.

10 ~~11~~. (original) The vaccine composition of claim 8 ~~9~~ further comprising a pharmaceutically acceptable adjuvant.

11 ~~12~~. (currently amended) The vaccine composition of claim 5 ~~6~~ wherein the isolated, attenuated viral strain is ~~the strain of claim 4~~ **selected from the group of viral strains consisting of those designated C3464, C3490, C3605, and subclones or progeny of any of the aforementioned strains**.

12 ~~13~~. (original) The vaccine composition of claim 11 ~~12~~ further comprising a pharmaceutically acceptable excipient.

13 ~~14~~. (original) The vaccine composition of claim 11 ~~12~~ further comprising a pharmaceutically acceptable adjuvant.

15. (canceled)

16. (canceled)

17. (canceled)

14 ~~18~~. (original) A method of inducing a protective immune response in a mammal comprising administering to the mammal an amount of the isolated, attenuated viral strain of claim 1 sufficient to elicit the protective immune response.

15 ~~19~~. (currently amended) The method of claim 14 ~~18~~ wherein the isolated, attenuated viral strain ~~is the strain of claim 2~~ **exhibits titers in plaque assays on Vero cells when grown at around 32°C in a mammalian host cell which are less than about 100 times its titer when grown at around 23°C in the mammalian host cell, and which are greater than or equal to about 100 times its titer when grown at around 39°C in the mammalian host cell**.

16 ~~20~~. (currently amended) The method of claim 14 ~~18~~ wherein the isolated, attenuated viral strain ~~is the strain of claim 3~~ **exhibits titers in plaque assays on Vero cells when grown at around 39°C in the mammalian host cell which are less than or equal to about 1.0 pfu/ml**.

17 ~~21~~. (currently amended) The method of claim 14 ~~18~~ wherein the isolated, attenuated viral strain is ~~the strain of claim 4~~ **selected from the group of viral strains consisting of those designated C3464, C3490, C3605, and subclones or progeny of any of the aforementioned strains**.

22. (canceled)

18 ~~23~~. (new) The isolated, attenuated viral strain of claim 1, wherein the viral strain is produced by a method comprising the steps of:

(a) culturing in vitro a wild type human parainfluenza virus 2 (HPIV-2);

(b) cold passaging said virus at a first temperature;

(c) selecting viruses that grow at the first temperature;

(d) cold passaging the selected viruses at a second temperature, the second temperature being less than the first; and

(e) selecting viruses that grow at the second temperature.

19 ~~24~~. (new) The isolated, attenuated viral strain of claim 18 ~~23~~, further comprising the steps of:

(f) cold passaging the selected viruses at a third temperature, the third temperature being less than the second; and

(g) selecting viruses that grow at the third temperature.

20 ~~25~~. (new) The isolated, attenuated viral strain of claim 19 ~~24~~, further comprising the steps of:

(h) cold passaging the selected viruses at a fourth temperature, the fourth temperature being less than the third; and

(i) selecting viruses that grow at the fourth temperature.

21 ~~26~~. (new) The isolated, attenuated viral strain of claim 18 ~~23~~, wherein the virus is passaged and selected more than once at each temperature.

22 ~~27~~. (new) The isolated, attenuated viral strain of claim 20 ~~25~~, wherein the virus is passaged and selected more than once at each temperature.

23 ~~28~~. (new) The isolated, attenuated viral strain of claim 22 ~~27~~, wherein the viruses are passaged at a first temperature of about 30°C, at a second temperature of about 28°C, at a third temperature of about 26°C, and at a fourth temperature of about 24°C.

24 ~~29~~. (new) The isolated, attenuated viral strain of claims 23 ~~28~~, wherein the viruses are passaged six times at 30°C, six times at 28°C, eight times at 26°C and thirteen times at 24°C.

25 ~~30~~. (new) A vaccine composition comprising the isolated, attenuated viral strain of claim 18 ~~23~~ and a pharmaceutically acceptable carrier.

26 ~~31~~. (new) A vaccine composition comprising the isolated, attenuated viral strain of claim 20 ~~25~~ and a pharmaceutically acceptable carrier.

27
~~32~~. (new) A method of inducing a protective immune response in a mammal comprising administering to the mammal an amount of the isolated, attenuated viral strain of claim 18 ~~23~~ sufficient to elicit the protective immune response.

28
~~33~~. (new) A method of inducing a protective immune response in a mammal comprising administering to the mammal an amount of the isolated, attenuated viral strain of claim 20 ~~25~~ sufficient to elicit the protective immune response.

29
~~34~~. (new) A method of producing an isolated, attenuated viral strain of human parainfluenza virus 2, wherein the viral strain is temperature sensitive and cold adapted, the method comprising the steps of:

(a) culturing in vitro a wild type human parainfluenza virus 2 (HPIV-2);

(b) cold passaging said virus at a first temperature;

(c) selecting viruses that grow at the first temperature;

(d) cold passaging the selected viruses at a second temperature, the second temperature being less than the first; and

(e) selecting viruses that grow at the second temperature.

30
~~35~~. (new) The method according to claim 29 ~~34~~, further comprising the steps of:

(f) cold passaging the selected viruses at a third temperature, the third temperature being less than the second; and

(g) selecting viruses that grow at the third temperature.

31 ~~36~~. (new) The method according to claim 30 ~~35~~, further comprising the steps of:

(h) cold passaging the selected viruses at a fourth temperature, the fourth temperature being less than the third; and

(i) selecting viruses that grow at the fourth temperature.

32 ~~37~~. (new) The method according to claim 29 ~~34~~, wherein the virus is passaged and selected more than once at each temperature.

33 ~~38~~. (new) The method according to claim 31 ~~36~~, wherein the virus is passaged and selected more than once at each temperature.

34 ~~39~~. (new) The method according to claim 33 ~~38~~, wherein the viruses are passaged at a first temperature of about 30°C, at a second temperature of about 28°C, at a third temperature of about 26°C, and at a fourth temperature of about 24°C.

35 ~~40~~. (new) The method according to claim 34 ~~39~~, wherein the viruses are passaged six times at 30°C, six times at 28°C, eight times at 26°C and thirteen times at 24°C.

36 ~~41~~. (new) The method according to claim 35 ~~40~~, wherein the isolated, attenuated viral strain exhibits titers in plaque assays on Vero cells when grown at around 32°C in a mammalian host cell which are less than about 100 times its titre when grown at around 23°C in the mammalian host cell, and which are greater than or equal to about 100 times its titre when grown at around 39°C in the mammalian host cell.

37 ~~42~~. (new) The method according to claim 36 ~~41~~, wherein the isolated attenuated viral strain exhibits titers in plaque assays on Vero cells when grown at around 39°C in the mammalian host cell which are less than or equal to about 1.0 pfu/ml.